512 related articles for article (PubMed ID: 30352240)
1. Sulforaphane induces autophagy by inhibition of HDAC6-mediated PTEN activation in triple negative breast cancer cells.
Yang F; Wang F; Liu Y; Wang S; Li X; Huang Y; Xia Y; Cao C
Life Sci; 2018 Nov; 213():149-157. PubMed ID: 30352240
[TBL] [Abstract][Full Text] [Related]
2. HDAC5-LSD1 axis regulates antineoplastic effect of natural HDAC inhibitor sulforaphane in human breast cancer cells.
Cao C; Wu H; Vasilatos SN; Chandran U; Qin Y; Wan Y; Oesterreich S; Davidson NE; Huang Y
Int J Cancer; 2018 Sep; 143(6):1388-1401. PubMed ID: 29633255
[TBL] [Abstract][Full Text] [Related]
3. Cantharidin Inhibits the Growth of Triple-Negative Breast Cancer Cells by Suppressing Autophagy and Inducing Apoptosis in Vitro and in Vivo.
Li HC; Xia ZH; Chen YF; Yang F; Feng W; Cai H; Mei Y; Jiang YM; Xu K; Feng DX
Cell Physiol Biochem; 2017; 43(5):1829-1840. PubMed ID: 29050003
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
5. Combination of the novel histone deacetylase inhibitor YCW1 and radiation induces autophagic cell death through the downregulation of BNIP3 in triple-negative breast cancer cells in vitro and in an orthotopic mouse model.
Chiu HW; Yeh YL; Wang YC; Huang WJ; Ho SY; Lin P; Wang YJ
Mol Cancer; 2016 Jun; 15(1):46. PubMed ID: 27286975
[TBL] [Abstract][Full Text] [Related]
6. Overcoming doxorubicin resistance in triple-negative breast cancer using the class I-targeting HDAC inhibitor bocodepsin/OKI-179 to promote apoptosis.
Smoots SG; Schreiber AR; Jackson MM; Bagby SM; Dominguez ATA; Dus ED; Binns CA; MacBeth M; Whitty PA; Diamond JR; Pitts TM
Breast Cancer Res; 2024 Mar; 26(1):35. PubMed ID: 38429789
[TBL] [Abstract][Full Text] [Related]
7. Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat.
Tate CR; Rhodes LV; Segar HC; Driver JL; Pounder FN; Burow ME; Collins-Burow BM
Breast Cancer Res; 2012 May; 14(3):R79. PubMed ID: 22613095
[TBL] [Abstract][Full Text] [Related]
8. Autophagic cell death and premature senescence: New mechanism of 5-fluorouracil and sulforaphane synergistic anticancer effect in MDA-MB-231 triple negative breast cancer cell line.
Milczarek M; Wiktorska K; Mielczarek L; Koronkiewicz M; Dąbrowska A; Lubelska K; Matosiuk D; Chilmonczyk Z
Food Chem Toxicol; 2018 Jan; 111():1-8. PubMed ID: 29104175
[TBL] [Abstract][Full Text] [Related]
9. Sulforaphene inhibits triple negative breast cancer through activating tumor suppressor Egr1.
Yang M; Teng W; Qu Y; Wang H; Yuan Q
Breast Cancer Res Treat; 2016 Jul; 158(2):277-86. PubMed ID: 27377973
[TBL] [Abstract][Full Text] [Related]
10. Combination of pan-histone deacetylase inhibitor and autophagy inhibitor exerts superior efficacy against triple-negative human breast cancer cells.
Rao R; Balusu R; Fiskus W; Mudunuru U; Venkannagari S; Chauhan L; Smith JE; Hembruff SL; Ha K; Atadja P; Bhalla KN
Mol Cancer Ther; 2012 Apr; 11(4):973-83. PubMed ID: 22367781
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of ROS production, autophagy or apoptosis signaling reversed the anticancer properties of Antrodia salmonea in triple-negative breast cancer (MDA-MB-231) cells.
Chang CT; Korivi M; Huang HC; Thiyagarajan V; Lin KY; Huang PJ; Liu JY; Hseu YC; Yang HL
Food Chem Toxicol; 2017 May; 103():1-17. PubMed ID: 28219700
[TBL] [Abstract][Full Text] [Related]
12. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.
Torres-Adorno AM; Lee J; Kogawa T; Ordentlich P; Tripathy D; Lim B; Ueno NT
Clin Cancer Res; 2017 Aug; 23(16):4780-4792. PubMed ID: 28465444
[No Abstract] [Full Text] [Related]
13. Toosendanin and isotoosendanin suppress triple-negative breast cancer growth via inducing necrosis, apoptosis and autophagy.
Zhang J; Yang F; Mei X; Yang R; Lu B; Wang Z; Ji L
Chem Biol Interact; 2022 Jan; 351():109739. PubMed ID: 34742683
[TBL] [Abstract][Full Text] [Related]
14. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, enhances radiosensitivity and suppresses lung metastasis in breast cancer in vitro and in vivo.
Chiu HW; Yeh YL; Wang YC; Huang WJ; Chen YA; Chiou YS; Ho SY; Lin P; Wang YJ
PLoS One; 2013; 8(10):e76340. PubMed ID: 24130769
[TBL] [Abstract][Full Text] [Related]
15. Additive Pharmacological Interaction between Cisplatin (CDDP) and Histone Deacetylase Inhibitors (HDIs) in MDA-MB-231 Triple Negative Breast Cancer (TNBC) Cells with Altered Notch1 Activity-An Isobolographic Analysis.
Wawruszak A; Luszczki JJ; Kalafut J; Okla K; Halasa M; Rivero-Muller A; Stepulak A
Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31357442
[TBL] [Abstract][Full Text] [Related]
16. Characterization of HJ-PI01 as a novel Pim-2 inhibitor that induces apoptosis and autophagic cell death in triple-negative human breast cancer.
Zhao YQ; Yin YQ; Liu J; Wang GH; Huang J; Zhu LJ; Wang JH
Acta Pharmacol Sin; 2016 Sep; 37(9):1237-50. PubMed ID: 27397540
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of aerobic glycolysis enhances the anti-tumor efficacy of Zoptarelin Doxorubicin in triple-negative breast cancer cells.
Gründker C; Wokoun U; Hellriegel M; Emons G
J Obstet Gynaecol Res; 2019 Jul; 45(7):1334-1342. PubMed ID: 31016845
[TBL] [Abstract][Full Text] [Related]
18. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
[TBL] [Abstract][Full Text] [Related]
19. Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125.
Seitz S; Buchholz S; Schally AV; Weber F; Klinkhammer-Schalke M; Inwald EC; Perez R; Rick FG; Szalontay L; Hohla F; Segerer S; Kwok CW; Ortmann O; Engel JB
BMC Cancer; 2014 Nov; 14():847. PubMed ID: 25410881
[TBL] [Abstract][Full Text] [Related]
20. Sulforaphane-cisplatin combination inhibits the stemness and metastatic potential of TNBCs via down regulation of sirtuins-mediated EMT signaling axis.
Sinha S; Sharma S; Sharma A; Vora J; Shrivastava N
Phytomedicine; 2021 Apr; 84():153492. PubMed ID: 33640782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
